Hao‐Lin Liu, Qin Wang, Kun Lian
Sep 15, 2019
Citations
0
Influential Citations
0
Citations
Quality indicators
Journal
Journal name not available for this finding
Abstract
Sacubitril/valsartan (LCZ696), a compound composed of sacubitril and valsartan, plays a role by targeting on renin-angiotensin aldosterone system and natriuretic peptide system, which represents a breakthrough in the treatment of heart failure (HF) recently. PARADIGM-HF trial showed that LCZ696 can significantly reduce death from cardiovascular causes, death from any causes and hospitalization for HF, and improve the symptoms and physical strength in patients with HF with reduced ejection fraction (HFrEF). Therefore, the updated European, American and Chinese guidelines for HF all recommended LCZ696 for patients with HFrEF. However, as a new drug, LCZ696 still has many problems to be addressed in the treatment of HF. This paper will summarize the clinical efficacy and existing problems of LCZ696 in the treatment of HF. Key words: Sacubitril/valsartan; Heart failure